Emmaus Life Sciences Inc (EMMA)

Currency in USD
0.01
0.00(0.00%)
Closed·
EMMA Scorecard
Full Analysis
Operates with a significant debt burden
Trading near 52-week Low
Fair Value
Day's Range
0.010.01
52 wk Range
0.010.05
Key Statistics
Prev. Close
0.01
Open
0.01
Day's Range
0.01-0.01
52 wk Range
0.01-0.05
Volume
2K
Average Volume (3m)
32.13K
1-Year Change
-71.43%
Book Value / Share
-0.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EMMA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Emmaus Life Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Emmaus Life Sciences Inc Company Profile

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its pipeline products include ELS004, a pharmaceutical grade L-glutamine that is in Phase 1 clinical trial to treat diverticulosis. The company’s preclinical stage products comprise ELS005 for the treatment of blood cancers; ELS003, a lab device/research tool to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. The company was founded in 2000 and is headquartered in Torrance, California.

Compare EMMA to Peers and Sector

Metrics to compare
EMMA
Peers
Sector
Relationship
P/E Ratio
−0.2x−0.3x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
0.0x1.1x2.6x
Price / LTM Sales
0.1x11.6x3.2x
Upside (Analyst Target)
-127.7%43.8%
Fair Value Upside
Unlock7.7%8.1%Unlock

Earnings

Latest Release
May 16, 2025
EPS / Forecast
-0.04 / --
Revenue / Forecast
2.40M / --
EPS Revisions
Last 90 days

EMMA Income Statement

FAQ

What Stock Exchange Does Emmaus Life Sciences Trade On?

Emmaus Life Sciences is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Emmaus Life Sciences?

The stock symbol for Emmaus Life Sciences is "EMMA."

What Is the Emmaus Life Sciences Market Cap?

As of today, Emmaus Life Sciences market cap is 638.66K.

What Is Emmaus Life Sciences's Earnings Per Share (TTM)?

The Emmaus Life Sciences EPS (TTM) is -0.07.

When Is the Next Emmaus Life Sciences Earnings Date?

Emmaus Life Sciences will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is EMMA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Emmaus Life Sciences Stock Split?

Emmaus Life Sciences has split 5 times.

How Many Employees Does Emmaus Life Sciences Have?

Emmaus Life Sciences has 35 employees.

What is the current trading status of Emmaus Life Sciences (EMMA)?

As of 01 Aug 2025, Emmaus Life Sciences (EMMA) is trading at a price of 0.01, with a previous close of 0.01. The stock has fluctuated within a day range of 0.01 to 0.01, while its 52-week range spans from 0.01 to 0.05.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.